Provided by Tiger Fintech (Singapore) Pte. Ltd.

PolyPid Ltd.

3.28
-0.0300-0.91%
Post-market: 3.290.0100+0.30%19:42 EDT
Volume:212.85K
Turnover:683.71K
Market Cap:33.43M
PE:-0.82
High:3.32
Open:3.26
Low:3.12
Close:3.31
Loading ...

PolyPid Is Maintained at Buy by Roth Capital

Dow Jones
·
19 Jun

PolyPid Is Maintained at Market Outperform by JMP Securities

Dow Jones
·
17 Jun

PolyPid price target lowered to $9 from $12 at Roth Capital

TIPRANKS
·
17 Jun

PolyPid (PYPD) Receives a Buy from Craig-Hallum

TIPRANKS
·
17 Jun

PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial

TIPRANKS
·
17 Jun

PolyPid price target lowered to $14 from $16 at Citizens JMP

TIPRANKS
·
17 Jun

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful Shield Ii Phase 3 Trial Results

THOMSON REUTERS
·
17 Jun

Press Release: PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Dow Jones
·
17 Jun

PolyPid (PYPD) Gets a Buy from Roth MKM

TIPRANKS
·
10 Jun

PolyPid Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 Jun

PolyPid’s D-PLEX100: Compelling Phase 3 Results and Strong Commercial Prospects Justify Buy Rating

TIPRANKS
·
09 Jun

PolyPid Ltd. : H.c. Wainwright Raises Target Price to $13 From $11

THOMSON REUTERS
·
09 Jun

BUZZ-PolyPid rises after treatment to prevent surgical site infections meets late-stage trial goal

Reuters
·
09 Jun

BRIEF-PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial

Reuters
·
09 Jun

PolyPid announces topline results from Phase 3 SHIELD II trial

TIPRANKS
·
09 Jun

PolyPid Ltd. Announces Plans to Submit NDA to FDA for D-PLEX100 in Early 2026 Following Positive Phase 3 Trial Results

Reuters
·
09 Jun

PolyPid Ltd - D-Plex(100) Meets Primary Efficacy Endpoint in Phase 3 Trial

THOMSON REUTERS
·
09 Jun

PolyPid Ltd - Study Shows 38% Reduction in Primary Endpoint Events With D-Plex(100)

THOMSON REUTERS
·
09 Jun

PolyPid Ltd - No Safety Concerns Raised by Independent Data Safety Monitoring Board in Shield Ii

THOMSON REUTERS
·
09 Jun

PolyPid Ltd - to Submit Nda to FDA in Early 2026

THOMSON REUTERS
·
09 Jun